CN114129615A - Rabdosia lophanthide composition and application thereof - Google Patents
Rabdosia lophanthide composition and application thereof Download PDFInfo
- Publication number
- CN114129615A CN114129615A CN202010917817.0A CN202010917817A CN114129615A CN 114129615 A CN114129615 A CN 114129615A CN 202010917817 A CN202010917817 A CN 202010917817A CN 114129615 A CN114129615 A CN 114129615A
- Authority
- CN
- China
- Prior art keywords
- parts
- composition
- panax
- rabdosia
- rabdosia lophanthide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241001183967 Isodon Species 0.000 title claims abstract description 152
- 239000000203 mixture Substances 0.000 title claims abstract description 58
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 50
- 241000196324 Embryophyta Species 0.000 claims abstract description 43
- 241000208343 Panax Species 0.000 claims abstract description 43
- 239000002994 raw material Substances 0.000 claims abstract description 28
- 239000004480 active ingredient Substances 0.000 claims abstract description 24
- 208000007848 Alcoholism Diseases 0.000 claims abstract description 20
- 208000025569 Tobacco Use disease Diseases 0.000 claims abstract description 18
- 201000007930 alcohol dependence Diseases 0.000 claims abstract description 18
- 206010057852 Nicotine dependence Diseases 0.000 claims abstract description 16
- 206010012335 Dependence Diseases 0.000 claims abstract description 14
- 201000006152 substance dependence Diseases 0.000 claims abstract description 14
- 208000011117 substance-related disease Diseases 0.000 claims abstract description 14
- 230000000391 smoking effect Effects 0.000 claims abstract description 8
- 240000005373 Panax quinquefolius Species 0.000 claims description 73
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 64
- 239000003814 drug Substances 0.000 claims description 49
- 241000208340 Araliaceae Species 0.000 claims description 37
- 238000002360 preparation method Methods 0.000 claims description 34
- 235000002791 Panax Nutrition 0.000 claims description 28
- 235000013305 food Nutrition 0.000 claims description 22
- 230000036541 health Effects 0.000 claims description 22
- 244000242564 Osmanthus fragrans Species 0.000 claims description 20
- 235000019083 Osmanthus fragrans Nutrition 0.000 claims description 20
- 239000000463 material Substances 0.000 claims description 18
- 239000002775 capsule Substances 0.000 claims description 10
- 239000008187 granular material Substances 0.000 claims description 10
- 239000007788 liquid Substances 0.000 claims description 10
- 239000003826 tablet Substances 0.000 claims description 8
- 241000628997 Flos Species 0.000 claims description 7
- 235000013361 beverage Nutrition 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 7
- 240000001008 Dimocarpus longan Species 0.000 claims description 5
- 235000000235 Euphoria longan Nutrition 0.000 claims description 5
- 235000008434 ginseng Nutrition 0.000 claims description 4
- 240000004371 Panax ginseng Species 0.000 claims description 3
- 235000002789 Panax ginseng Nutrition 0.000 claims description 3
- 241000180649 Panax notoginseng Species 0.000 claims description 3
- 235000003143 Panax notoginseng Nutrition 0.000 claims description 3
- 239000002417 nutraceutical Substances 0.000 claims description 2
- 235000021436 nutraceutical agent Nutrition 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 2
- 229940127557 pharmaceutical product Drugs 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 37
- 230000002929 anti-fatigue Effects 0.000 abstract description 6
- 208000029650 alcohol withdrawal Diseases 0.000 abstract description 3
- 230000005586 smoking cessation Effects 0.000 abstract description 2
- 241000699670 Mus sp. Species 0.000 description 41
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 28
- 229960002715 nicotine Drugs 0.000 description 28
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 28
- 239000000047 product Substances 0.000 description 27
- 229940079593 drug Drugs 0.000 description 25
- 238000000034 method Methods 0.000 description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 20
- 206010070834 Sensitisation Diseases 0.000 description 19
- 230000008313 sensitization Effects 0.000 description 19
- 230000006399 behavior Effects 0.000 description 17
- 241000699666 Mus <mouse, genus> Species 0.000 description 16
- 230000008569 process Effects 0.000 description 16
- 238000002156 mixing Methods 0.000 description 15
- 238000005303 weighing Methods 0.000 description 13
- 241001122767 Theaceae Species 0.000 description 12
- 235000013616 tea Nutrition 0.000 description 12
- 235000019082 Osmanthus Nutrition 0.000 description 10
- 241000333181 Osmanthus Species 0.000 description 10
- 238000001914 filtration Methods 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 230000003542 behavioural effect Effects 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 8
- 244000061176 Nicotiana tabacum Species 0.000 description 7
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 7
- 238000004806 packaging method and process Methods 0.000 description 7
- 235000019640 taste Nutrition 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 238000012549 training Methods 0.000 description 7
- 239000002671 adjuvant Substances 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 230000009182 swimming Effects 0.000 description 5
- 241001533433 Isodon serra Species 0.000 description 4
- 239000006286 aqueous extract Substances 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 230000035622 drinking Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- 244000131316 Panax pseudoginseng Species 0.000 description 3
- 235000003181 Panax pseudoginseng Nutrition 0.000 description 3
- 230000002567 autonomic effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 235000014655 lactic acid Nutrition 0.000 description 3
- 239000004310 lactic acid Substances 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 238000010298 pulverizing process Methods 0.000 description 3
- 239000000779 smoke Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
- 244000241872 Lycium chinense Species 0.000 description 2
- 235000015468 Lycium chinense Nutrition 0.000 description 2
- 244000185386 Thladiantha grosvenorii Species 0.000 description 2
- 235000011171 Thladiantha grosvenorii Nutrition 0.000 description 2
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 239000003655 absorption accelerator Substances 0.000 description 2
- 239000003463 adsorbent Substances 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 201000001352 cholecystitis Diseases 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000001143 conditioned effect Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 210000000232 gallbladder Anatomy 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000003906 humectant Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000002791 soaking Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 230000002747 voluntary effect Effects 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 208000000197 Acute Cholecystitis Diseases 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 206010008614 Cholecystitis acute Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 241001183964 Isodon lophanthoides Species 0.000 description 1
- 241000637182 Isodon lophanthoides var. gerardianus Species 0.000 description 1
- 241000207923 Lamiaceae Species 0.000 description 1
- 235000017784 Mespilus germanica Nutrition 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 244000182216 Mimusops elengi Species 0.000 description 1
- 235000000560 Mimusops elengi Nutrition 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 235000007837 Vangueria infausta Nutrition 0.000 description 1
- 235000006545 Ziziphus mauritiana Nutrition 0.000 description 1
- 244000126002 Ziziphus vulgaris Species 0.000 description 1
- 235000008529 Ziziphus vulgaris Nutrition 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000002180 anti-stress Effects 0.000 description 1
- 235000019606 astringent taste Nutrition 0.000 description 1
- 239000010620 bay oil Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 208000020694 gallbladder disease Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 235000015092 herbal tea Nutrition 0.000 description 1
- 231100000003 human carcinogen Toxicity 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
- A61K36/725—Ziziphus, e.g. jujube
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/77—Sapindaceae (Soapberry family), e.g. lychee or soapberry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Addiction (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Toxicology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a rabdosia lophanthide composition for preventing or treating addiction substance dependence and application thereof. The active ingredients of the rabdosia lophanthide composition are prepared from the following raw materials: rabdosia lophanthide and Araliaceae Panax plant. The rabdosia lophanthide composition can effectively prevent alcohol and nicotine dependence, promote smoking cessation and alcohol withdrawal of people with smoking and alcohol addiction, simultaneously has good anti-fatigue effect, and can well improve the mouthfeel.
Description
Technical Field
The invention relates to the field of food and medicine, in particular to a rabdosia lophanthide composition and application thereof.
Background
Tobacco and alcohol are addictive substances widely used in social activities and prone to physical dependence and mental dependence. Tobacco and alcohol dependence are identified as neuropsychiatric diseases, and as chronic, highly recurrent addictive diseases. Smoking and drinking, which are major risk factors for chronic diseases, not only play a role in some diseases alone, but also increase the risk of esophageal cancer, metabolic syndrome, and the like through interaction. Tobacco smoke contains various carcinogens, ethanol metabolite acetaldehyde in alcohol, and is also determined as a human carcinogen by the international cancer organization. Meanwhile, the ethanol can stimulate the gastrointestinal tract and promote the absorption of carcinogenic substances in the tobacco smoke. Nicotine in alcohol and tobacco smoke reacts in the brain, increasing the human body's dependence on both addictive substances. Alcohol promotes the stimulation of nicotine, thereby promoting smoking.
With the rapid development of economy, China has become the biggest world-wide country for producing and consuming tobacco and alcohol, and smoking and drinking become major public health problems affecting the health of people in China. However, the available drugs for treating nicotine dependence or alcohol dependence are very limited, and the compliance of drinking and smokers with the corresponding drug treatment is also very low. Therefore, by improving the daily life style, the Chinese herbal medicine which is homologous in medicine and food is adopted for preventing and treating the tobacco and alcohol dependence, which is a deserved treatment means.
Rabdosia lophanthide is dry whole herb of Rabdosia lophanthide of Labiatae, is cold in nature, bitter in taste, enters liver and gallbladder channels, has the effects of clearing heat and promoting diuresis, cooling blood and removing blood stasis, and is used for treating acute icteric hepatitis, acute cholecystitis, enteritis, dysentery, swelling and pain due to traumatic injury and the like. At present, the rabdosia lophanthide and the compound preparation thereof are mainly applied to liver and gallbladder diseases such as hepatitis B, hepatitis C, cholecystitis and the like clinically, the rabdosia lophande is often used as a raw material of herbal tea for clearing liver and benefiting gallbladder in folk, and the rabdosia lophande is cold in taste and bitter in taste and is difficult to be accepted by the public by single use. Rabdosia lophanthide (Isodonlophanthoidesvar. gerardianus (Benth) H.Hara) is the mainstream variety in the Guangdong region, and is listed as a new food raw material catalog by the national health council in 2013.
Disclosure of Invention
Based on this, the object of the present invention is to provide a rabdosia lophanthide composition for preventing or treating addiction substance dependence, which has a good therapeutic effect on alcohol or nicotine dependence and also has a good anti-fatigue effect.
The specific technical scheme is as follows:
the linearstripe rabdosia herb composition for preventing or treating addiction substance dependence comprises the following active ingredients: rabdosia lophanthide and Araliaceae Panax plant.
In some embodiments, the active ingredients are prepared from the following raw materials in parts by weight: 1-100 parts of linearstripe rabdosia herb and 1-100 parts of a plant of the genus Panax of the family Araliaceae.
In some of these embodiments, the plant of the genus Panax of the family Araliaceae comprises at least one of Panax quinquefolium, Panax ginseng and Panax notoginseng.
In some embodiments, the active ingredients are prepared from the following raw materials in parts by weight: 1-20 parts of rabdosia lophanthide and 1-20 parts of a plant of the genus Panax of the family Araliaceae; further, 1-10 parts of rabdosia lophanthide and 1-10 parts of a plant of the genus Panax of the family Araliaceae, or 1-10 parts of rabdosia lophanthide and 1-2 parts of a plant of the genus Panax of the family Araliaceae. Further, the mass ratio of the linearstripe rabdosia herb to the plant of the genus Panax of the family Araliaceae is selected from 1:1, 2:3, 3:1, 3:2, 3:4, 4:1, 4:3, 4:5, 5:1, 5:3, 5:4, 5:6, 10:1, 20:1, 30:1, 40:1, 1:2, 1:3, 1:4, 1:5, or ranges between any two of the above.
The invention also provides another rabdosia lophanthide composition for preventing or treating addiction substance dependence, which improves mouthfeel, and the active ingredients of the rabdosia lophanthide composition are prepared from the following raw materials: herba Rabdosiae Lophanthoidis, plant of Panax of Araliaceae, and at least one of flos Osmanthi Fragrantis, fructus Jujubae, fructus Lycii, arillus longan and fructus Siraitiae Grosvenorii.
In some embodiments, the active ingredients of the rabdosia lophanthide composition are prepared from the following raw materials in parts by weight: 1-100 parts of linearstripe rabdosia herb, 1-100 parts of a plant of the genus Panax of the family Araliaceae, and at least one of 1-100 parts of sweet osmanthus, 1-100 parts of red date, 1-100 parts of medlar, 1-100 parts of longan and 1-100 parts of momordica grosvenori.
In some embodiments, the active ingredient of the rabdosia lophanthide composition is prepared from the following raw materials: herba Rabdosiae Lophanthoidis, Panax plant of Araliaceae, and flos Osmanthi Fragrantis.
In some embodiments, the active ingredients of the rabdosia lophanthide composition are prepared from the following raw materials in parts by weight: 1-100 parts of linearstripe rabdosia herb, 1-100 parts of a plant of the genus Panax of the family Araliaceae and 1-100 parts of sweet osmanthus flower.
In some embodiments, the active ingredients of the rabdosia lophanthide composition are prepared from the following raw materials in parts by weight: 1-20 parts of rabdosia lophanthide, 1-2 parts of araliaceae ginseng plant and 1-2 parts of osmanthus fragrans; further, 1-10 parts of rabdosia lophanthide, 1-2 parts of araliaceae ginseng plant and 1-2 parts of osmanthus fragrans; further, 3-10 parts of rabdosia lophanthide, 1-2 parts of araliaceae ginseng plant and 1-2 parts of osmanthus fragrans; further, 3-5 parts of rabdosia lophanthide, 1 part of panax plant of araliaceae and 0.5-2 parts of osmanthus flower, further 4 parts of rabdosia lophanthide, 1 part of panax plant of araliaceae and 1 part of osmanthus flower.
In some embodiments, the active ingredient of the rabdosia lophanthide composition is prepared from the following raw materials: herba Rabdosiae Lophanthoidis, Panax plant of Araliaceae, and fructus Jujubae.
In some embodiments, the active ingredients of the rabdosia lophanthide composition are prepared from the following raw materials in parts by weight: 1-100 parts of rabdosia lophanthide, 1-100 parts of panax plants of araliaceae and 1-100 parts of red dates, and further 1-10 parts of rabdosia lophanthide, 1-10 parts of panax plants of araliaceae and 1-10 parts of red dates; further comprises 1-10 parts of linearstripe rabdosia herb, 1-2 parts of araliaceae ginseng plant and 1-2 parts of red date.
In some embodiments, the active ingredient of the rabdosia lophanthide composition is prepared from the following raw materials: herba Rabdosiae Lophanthoidis, Araliaceae Panax plant, flos Osmanthi Fragrantis and fructus Jujubae.
In some embodiments, the active ingredients of the rabdosia lophanthide composition are prepared from the following raw materials in parts by weight: 1-100 parts of linearstripe rabdosia herb, 1-100 parts of a plant of the genus Panax of the family Araliaceae, 1-100 parts of sweet osmanthus flower and 1-100 parts of red date. Further, the traditional Chinese medicine composition comprises 1-25 parts of rabdosia lophanthide, 1-2 parts of araliaceae ginseng plants, 1-2 parts of osmanthus fragrans and 1-2 parts of red dates. Further, the traditional Chinese medicine composition comprises 3-10 parts of rabdosia lophanthide, 1-2 parts of araliaceae ginseng plants, 1-2 parts of osmanthus fragrans and 1-2 parts of red dates.
The invention also aims to provide application of the rabdosia lophanthide composition in preparing a product for preventing or treating addiction to substance dependence.
In some of these embodiments, the addictive substance dependence is an alcohol or nicotine dependence.
The invention also aims to provide application of the rabdosia lophanthide composition in preparing a product for abstaining from alcohol or quitting smoking.
Still another object of the present invention is to provide a product for preventing or treating addiction material dependence, which comprises the above-mentioned linearstripe rabdosia herb composition, and auxiliary materials.
In some of these embodiments, the product is a nutraceutical, food, or pharmaceutical.
In some embodiments, the food is in the form of a teabag, a beverage, a granular food, a powdered food, a encapsulated food, or a flaked food.
In some embodiments, the health product is in the form of liquid health product, granular health product, powder health product, capsule health product or tablet health product.
In some embodiments, the pharmaceutical product is in the form of oral liquid, granules, powder, capsules or tablets.
In some of these embodiments, the excipient comprises at least one of an excipient, a filler, a compatibilizer, a binder, a humectant, a disintegrant, a demulcent, an absorption accelerator, an adsorbent, a diluent, a solubilizer, an emulsifier, a lubricant, a wetting agent, a suspending agent, a flavoring agent, and a fragrance.
Compared with the prior art, the invention has the following beneficial effects:
the rabdosia lophanthide composition is prepared by compounding rabdosia lophanthide and araliaceae ginseng plants, can weaken reward effect caused by alcohol or nicotine dependence, inhibit the formation and expression of behavior sensitization caused by alcohol or nicotine, effectively prevent and treat alcohol and nicotine dependence, promote smoking cessation and alcohol addiction crowds to quit smoking and alcohol withdrawal, and simultaneously have good anti-fatigue effect and can well improve mouthfeel.
In addition, the rabdosia lophanthide composition has good long-term use safety and good use compliance.
Detailed Description
Experimental procedures according to the invention, in which no particular conditions are specified in the following examples, are generally carried out under conventional conditions, or under conditions recommended by the manufacturer. The various chemicals used in the examples are commercially available.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. The terminology used in the description of the invention herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention.
The terms "comprising" and "having," and any variations thereof, are intended to cover non-exclusive inclusions. For example, a process, method, apparatus, article, or device that comprises a list of steps is not limited to only those steps or modules listed, but may alternatively include other steps not listed or inherent to such process, method, article, or device.
The "plurality" referred to in the present invention means two or more. "and/or" describes the association relationship of the associated objects, meaning that there may be three relationships, e.g., a and/or B, which may mean: a exists alone, A and B exist simultaneously, and B exists alone. The character "/" generally indicates that the former and latter associated objects are in an "or" relationship.
One embodiment of the invention provides a rabdosia lophanthide composition for preventing or treating addiction substance dependence, which comprises the following active ingredients: rabdosia lophanthide and Araliaceae Panax plant.
Wherein, in some embodiments, the rabdosia lophanthide can be combined with the plant of the genus Panax of the family Araliaceae in any mass ratio, for example, 1 to 100 parts by weight of rabdosia lophanthide and 1 to 100 parts by weight of the plant of the genus Panax of the family Araliaceae; for example, 1 to 20 parts of linearstripe rabdosia herb and 1 to 20 parts of a plant of the genus Panax of the family Araliaceae; further, 1-10 parts of rabdosia lophanthide
And 1-10 parts of a plant belonging to the genus Panax of the family Araliaceae. Or 1-10 parts of rabdosia lophanthide and 1-2 parts of a plant of the genus Panax of the family Araliaceae. For example, the mass ratio of the linearstripe rabdosia herb to the plant of the genus panax of the family araliaceae is selected from 1:1, 2:3, 3:1, 3:2, 3:4, 4:1, 4:3, 4:5, 5:1, 5:3, 5:4, 5:6, 10:1, 20:1, 30:1, 40:1, 1:2, 1:3, 1:4, 1:5, or a range between any two of the foregoing.
In some embodiments, the linearstripe rabdosia herb comprises a crude linearstripe rabdosia herb or an extract of linearstripe rabdosia herb, and other processed products that do not affect the activity of linearstripe rabdosia herb; the plant of Panax genus of Araliaceae family includes crude drug or extract thereof, and other processed products without affecting the activity of plant of Panax genus of Araliaceae family.
In some embodiments, the plant of the genus Panax of the family Araliaceae comprises at least one of Panax quinquefolium, Panax ginseng and Panax notoginseng.
The embodiment also provides a rabdosia lophanthide composition for preventing or treating addiction substance dependence, which has improved mouthfeel, and the active ingredients of the rabdosia lophanthide composition are prepared from the following raw materials: herba Rabdosiae Lophanthoidis, plant of Panax of Araliaceae, and at least one of flos Osmanthi Fragrantis, fructus Jujubae, fructus Lycii and fructus Siraitiae Grosvenorii. The above herba Rabdosiae Lophanthoidis and Panax plant of Araliaceae can be combined with at least one of flos Osmanthi Fragrantis, fructus Jujubae, fructus Lycii, arillus longan and fructus Siraitiae Grosvenorii at any ratio.
In some embodiments, the osmanthus fragrans comprises crude osmanthus fragrans or an osmanthus fragrans extract or osmanthus fragrans oil.
In some embodiments, the raw materials of the active ingredient of the rabdosia lophanthide composition are rabdosia lophanthide, araliaceae panax plant and osmanthus fragrans. Wherein the rabdosia lophanthide and the panax plant of the Araliaceae can be combined with the osmanthus by any weight parts, for example, 1 to 100 parts of rabdosia lophanthide, 1 to 100 parts of panax plant of the Araliaceae and 1 to 100 parts of osmanthus by weight parts.
In some embodiments, the raw materials of the active ingredient of the rabdosia lophanthide composition are rabdosia lophanthide, araliaceae ginseng genus plant, osmanthus fragrans and red date. Wherein, the rabdosia lophanthide and the araliaceae ginseng plant can be combined with the sweet osmanthus and the red date in any weight portion. For example, the ingredients include, by weight, 1 to 100 parts of linearstripe rabdosia herb, 1 to 100 parts of a plant belonging to the genus Panax of the family Araliaceae, 1 to 100 parts of osmanthus fragrans, and 1 to 100 parts of red dates.
In another embodiment of the invention, the application of the linearstripe rabdosia herb composition in preparing a product for preventing or treating addiction to substance dependence is further provided.
In some embodiments, the addictive substance dependence is an alcohol or nicotine dependence.
In another embodiment of the invention, the application of the rabdosia lophanthide composition in preparing a product for abstaining from alcohol or quitting smoking is further provided.
Still another object of the present invention is to provide a product for preventing or treating addiction material dependence, which comprises the above-mentioned linearstripe rabdosia herb composition, and auxiliary materials.
The product of the embodiment can be a health product, food or medicine.
The product according to the present embodiment is not limited to the dosage form, and the food may be any conventional dosage form such as a teabag, a beverage, a granular food, a powdered food, a capsule-like food, or a tablet-like food. The health care product is any conventional dosage form such as liquid health care product, granular health care product, powdery health care product, capsule health care product or sheet health care product; the medicine is any conventional dosage form such as oral liquid, granule, powder, capsule or tablet
In this embodiment, the adjuvant is any adjuvant acceptable in the preparation of medicines, health products and foods, and is selected from any one or more of excipients, fillers, bulking agents, binders, humectants, disintegrating agents, slow-dissolving agents, absorption accelerators, adsorbents, diluents, solubilizers, emulsifiers, lubricants, wetting agents, suspending agents, flavoring agents and perfumes.
The present invention will be described in further detail with reference to specific examples.
First, study of Activity
1 Activity research method
1.1 test animals, reagents and groups
Healthy male C57 mice (18-22 g in weight) were provided by the laboratory animals of Viton Hua, Beijing under the license number SCXK (Jing) 2016-. Feeding in common animal laboratory (temperature: 22 deg.C + -1 deg.C, humidity: 60% + -5%), feeding with standard feed, and drinking purified water.
Mice were allowed to incubate at 12 h: adapting to 7 days in 12h day-night alternating environment, 105C 57 mice were randomly divided into 7 groups of 15 mice each, which were: normal control group (normal saline 0.5g/kg + normal saline), model group (normal saline 0.5g/kg + alcohol or nicotine), rabdosia lophanthide group (rabdosia lophanthide 0.5g/kg + alcohol or nicotine), american ginseng group (american ginseng 0.5g/kg + alcohol or nicotine), rabdosia lophanthide + american ginseng group 1 (rabdosia lophanthide 0.5g/kg + american ginseng 0.5g/kg + alcohol or nicotine), rabdosia lophane + american ginseng group 2 (rabdosia lophanthide 0.6g/kg + american ginseng 0.3g/kg + alcohol or nicotine), rabdosia lophane + american ginseng group 3 (rabdosia lophanthide 0.8g/kg + american ginseng 0.2g/kg + alcohol or nicotine). Wherein the dose of alcohol administered per time is 2g/kg, and the dose of nicotine administered is 0.5 mg/kg. The rabdosia lophanthide is used for administration, and the preparation process comprises the following steps: taking 100g of dried rabdosia lophanthide whole herb, adding 600ml of water, decocting for 2 times, wherein the decocting time is 1 hour each time, combining the decoctions, and concentrating to obtain the concentrated rabdosia lophanthide whole herb with the relative density of 1.12-1.20 (55-60 ℃) for later use. The American ginseng used for administration is an American ginseng aqueous extract, and the preparation method of the American ginseng aqueous extract refers to a rabdosia lophanthide aqueous extract. The group of the rabdosia lophanthide and the American ginseng used for administration is an aqueous extract of the rabdosia lophanthide and the American ginseng.
1.2 methods of administration
The rabdosia lophanthide group, the American ginseng group and the combined medicine group (rabdosia lophanthide and American ginseng group 1, 2 and 3) are administered with the medicine, and rats in the normal control group and the model group are gavaged with physiological saline with the same volume.
1.3 alcohol/Nicotine dependence modeling
1.3.1 conditional location preference model
Animal models of Conditional Positional Preference (CPP) are a common method for assessing the rewarding and dependence effects of addictive substances such as alcohol, nicotine, etc. A general experiment comprises three stages: a base value pretest phase, a conditional location preference training phase and a test phase. On day 1 of the experiment, the isolation door in the CPP box was opened to allow the mice to explore freely between the black and white boxes. The residence time in the black and white boxes within 15min was recorded, and the preference of each mouse for CPP in the black and white boxes was determined. Mice with a natural preference for black or white boxes (dwell >500s) were culled according to basal values. The experiment comprises 4 training rounds on 2-9 days. According to the basic value, a non-preferential case of the mouse is used as a medicine accompanying case, a white case is used as the medicine accompanying case in the experiment, and a black case is used as the non-medicine accompanying case. Injecting normal saline into abdominal cavity on 2, 4, 6 and 8 days of training for 5min, placing into non-accompanied medicine box, staying for 30min, and taking out. Administering addictive substance (alcohol or nicotine) for 5min on 3, 5, 7 and 9 days of training, placing into a companion medicine box, standing for 30min, and taking out. The normal control group and the model group of mice are given gastric lavage normal saline 30min before training on the 2 nd to 9 th days, and the rabdosia lophanthide group, the American ginseng group and the combined administration group (1, 2, 3) are given corresponding drugs 30min before training on the 2 nd to 9 th days.
After 4 rounds of training, the test was performed on day 10 with no drug administration on the day of the test. And (4) removing the middle isolation door, putting the mouse into the middle isolation door, freely selecting the mouse between the two boxes, and recording the residence time of the mouse in the medicine accompanying box and the non-medicine accompanying box within 15min respectively.
1.3.2 behavioral sensitization experiments
Behavioral sensitization refers to the process of progressive enhancement of the body's behavioral response caused by chronic intermittent administration of addictive substances. Before the experiment, the mice are adapted to a test room for at least 1h, normal saline is injected into the abdominal cavity according to the body weight, the mice are immediately placed in the center of an open box, the mice freely explore in the open box for 15min, and the activity times of the mice are recorded and used as the basic activity value of the mice. From the next day, the control group and the model group are administered with normal saline with equal volume by intragastric administration, and the rabdosia lophanthide group, the American ginseng group and the combined drug (1, 2, 3) group are administered with drugs with corresponding dose according to the weight 1 time per day for 7 days continuously. The control group was injected subcutaneously with normal saline, other groups with subcutaneous alcohol or nicotine 1 time per day for 7 consecutive days 1 hour after daily administration. (1) Formation of behavioral sensitization: stopping using alcohol or nicotine for 4 days on day 8 without any treatment; all animals were challenged with subcutaneous alcohol or nicotine on day 12 and the number of voluntary events in the mice was immediately determined within 30 minutes. (2) Expression of behavioral sensitization: stopping using alcohol or nicotine for 4 days on day 8, and administering normal saline with equal volume to control group and model group, and administering herba Rabdosiae Lophanthoidis, radix Panacis Quinquefolii or combination group (1, 2, 3) to medicine group for 4 days. All animals were challenged with subcutaneous injections of addictive substances on day 12, and the number of voluntary activities in the mice was immediately determined within 30 minutes
1.3.3 anti-fatigue study
C57 mice were fed adaptively for 1 week, and were randomly divided into a blank control group, a Rabdosia serra (Hemsl.) Hara group (0.5g/kg), an American ginseng group (0.5g/kg), and a combined drug group (group 1: Rabdosia serra (Hemsl.) Hara 0.5g/kg + American ginseng 0.5g/kg, group 2: Rabdosia serra (Hemsl.) Hara 0.6g/kg + American ginseng 0.3g/kg, group 3: Rabdosia serra (Hemsl.) Hara 0.8g/kg + American ginseng 0.2 g/kg). Each group of mice was administered by gavage 1 time daily for 14 days. 30min after the last administration, lead wires with 6 percent of the weight of the negative bodies at the tail of the mouse are placed in water for swimming, and the time from the entry of the mouse into the water to the exhaustion of the swimming is recorded, wherein the exhaustion standard is the time that the head of the mouse can not float upwards when the head of the mouse is completely immersed in the water. 30min after swimming, collecting mouse serum, and measuring the content of serum urea nitrogen (BUN) and serum Lactic Acid (LA) with a semi-automatic spectrophotometer.
1.4 data analysis
Experimental data on
The form is expressed, SPSS19.0 software is used for carrying out one-factor variance analysis on the data, and an LSD method is used for pairwise comparison among groups.
2. Results of the study
3.1 Effect of different proportions of Rabdosia lophanthide and American ginseng on nicotine dependence
As shown in Table 1, the results of the preliminary stage of the baseline values indicate that the mice in each group have no obvious difference in the residence time of the concomitant drug box, and the difference has no statistical significance (P >0.05), which indicates that the preference degrees of the mice in each group for the concomitant drug box are similar. Compared with a normal control group, the residence time of the mice in the nicotine dependence model group in the concomitant drug box (white box) is obviously prolonged, the preference degree of the mice on the concomitant drug box is obviously improved (P <0.01), the obvious reward effect is generated by nicotine, and the mice establish the correlation between the nicotine reward effect and the concomitant drug box. Compared with a nicotine dependence model group, the rabdosia lophanthide and American ginseng composition in different proportions obviously reduce the residence time (P <0.01) of a nicotine dependence mouse in a medicine accompanying box, and the residence time of the American ginseng mouse in the medicine accompanying box is not obviously different from that of the model group.
TABLE 1 Effect of Rabdosia lophanthide and American ginseng on Nicotine-induced conditioned Locus preference ((
n＝10)。
# P <0.001vs normal control group; p <0.05, P <0.01vs nicotine dependence model group.
3.2 Effect of different proportions of Rabdosia lophanthide and American ginseng on alcohol dependence
As shown in Table 2, the results of the preliminary stage of the baseline values showed that the residence time of each group of mice in the concomitant drug box was not significantly different, and the differences were not statistically significant (P >0.05), indicating that the preference degrees of each group of mice for the concomitant drug box were similar. Compared with a normal control group, the residence time of the mice in the alcohol dependence model group in the concomitant drug box (white box) is obviously prolonged, the preference degree of the mice in the concomitant drug box is obviously improved (P <0.01), the obvious reward effect is generated by alcohol, and the relevance between the alcohol reward effect and the concomitant drug box is established for the mice. Compared with an alcohol dependence model group, the rabdosia lophanthide and American ginseng composition in different proportions obviously reduce the residence time (P <0.01) of an alcohol dependence mouse in a medicine accompanying box, and the residence time of the American ginseng mouse in the medicine accompanying box is not obviously different from that of the model group.
TABLE 2 influence of different ratios of Rabdosia lophanthide and American ginseng on alcohol-induced conditioned place preference (
n＝10)。
# P <0.001vs normal control group; p <0.05, P <0.01vs alcohol dependence model group.
3.3 Effect of different proportions of Rabdosia Lophanthoides and American Ginseng on Nicotine-induced behavioral sensitization
As shown in table 3, there was no significant difference in basal activity values (P >0.05) among the groups of mice, i.e., the mice had similar autonomic activity behaviors. In the behavioral sensitization development phase, the number of nicotine-dependent mouse activities was significantly increased compared to the normal control group, indicating that nicotine sensitizes the behavior of mice (P < 0.01). Compared with a nicotine dependence model group, the rabdosia lophanthide and American ginseng composition with different proportions can obviously reduce the times of autonomous activities of the behavior sensitized mice (P is less than 0.01, and P is less than 0.001), and the rabdosia lophanthide can effectively inhibit the formation of the behavior sensitization of the mice caused by nicotine. The administration is kept during the behavioral sensitization expression stage, namely nicotine withdrawal, and compared with a normal control group, the number of autonomic activities of the nicotine-dependent mice is remarkably increased (P < 0.01); the rabdosia lophanthide and American ginseng composition in different proportions reduce behavior sensitization expression excited by small dose of nicotine, the difference has statistical significance, and the American ginseng has no effect on the formation and expression of behavior sensitization induced by nicotine when being singly administered.
TABLE 3 Effect of various ratios of Rabdosia lophanthide and American ginseng on sensitization of nicotine-induced behavior: (
n＝10)。
The # P is less than 0.001vs normal control group; p <0.05, P <0.01, P <0.001vs nicotine dependence model group.
3.4 Effect of different proportions of Rabdosia lophanthide and American ginseng on sensitization of alcohol-induced behavior
As shown in table 4, there was no significant difference in basal activity values (P >0.05) among the groups of mice, i.e., the mice had similar autonomic activity behaviors. During the behavioral sensitization development phase, the number of activities of the alcohol-dependent mice was significantly increased compared to the normal control group, indicating that alcohol sensitized the behavior development of the mice (P < 0.01). Compared with an alcohol dependence model group, the rabdosia lophanthide and American ginseng composition with different proportions can obviously reduce the number of times of autonomous activities of the behavior sensitized mice (P is less than 0.01, and P is less than 0.001), and the rabdosia lophanthide can effectively inhibit the formation of the behavior sensitization of the mice caused by alcohol. The administration is kept during the behavioral sensitization expression stage, namely the alcohol withdrawal period, and the number of autonomous activities of the alcohol-dependent mice is remarkably increased (P <0.01) compared with that of a normal control group; the rabdosia lophanthide and American ginseng composition in different proportions reduce behavior sensitization expression excited by small amount of alcohol, the difference has statistical significance, and the American ginseng has no effect on the formation and expression of behavior sensitization induced by the alcohol when being singly administered.
TABLE 4 influence of different proportions of Rabdosia lophanthide and American ginseng on sensitization of alcohol-induced behavior: (
n＝10)。
The # P is less than 0.001vs normal control group; p <0.01, P <0.001vs alcohol dependence model group.
3.5 Rabdosia lophanthide and American ginseng in different proportions for resisting fatigue
The time from swimming to exhaustion is the comprehensive reaction of the physical ability of the mice, which not only reflects the fatigue resistance of the body, but also reflects the anti-stress capability and the adaptability to adverse environment of the body. The test result shows that the American ginseng and the composition of the American ginseng and the rabdosia lophanthide can obviously prolong the time from swimming to exhaustion of mice, wherein the effect is most obvious when the American ginseng is matched with the rabdosia lophanthide in a ratio of 1:1, and the rabdosia lophanthide has no obvious effect when being singly administered. In addition, the American ginseng and the composition of the American ginseng and the rabdosia lophanthide can obviously reduce the content of urea nitrogen and lactic acid in serum of a sport mouse. The results show that the American ginseng and the composition of the American ginseng and the rabdosia lophanthide have the anti-fatigue effect.
TABLE 5 anti-fatigue effects of herba Rabdosiae Lophanthoidis and radix Panacis Quinquefolii at different ratios: (
n＝10)。
P <0.05, P <0.01vs solvent control.
Taste degree of rabdosia lophanthide composition in different proportions
The rabdosia lophanthide has special green grass flavor, is bitter and astringent in taste, is not high in public acceptance degree, and improves the taste through screening different medicinal materials and screening according to proportions. The following table shows the substances and the mixture ratio with good mouthfeel.
Materials: the rabdosia lophanthide, the American ginseng, the pseudo-ginseng, the sweet osmanthus flower and the red date are all dry products, and are mixed according to the mixture ratio shown in table 6 and then are brewed with hot water, wherein the ratio of the rabdosia lophanthide composition to the water is 1: and 50, carrying out a mouthfeel test.
As shown in Table 6, the results of this experiment show that the herb Rabdosia Lophanthoidis composition has a clear and beautiful soup color, reduced bitter taste and astringent taste in other proportions, and the best effect is achieved by the 7 th and 8 th groups.
TABLE 6 taste of Rabdosia lophanthide composition at different ratios
Preparation of herba Rabdosiae Lophanthoidis product
Example 1
Preparation of tablets
Weighing the following formula, and preparing the tablet by the process
Rabdosia lophanthide 2000g
American ginseng 200g
Chinese date 50g
Chinese wolfberry fruit 50g
Proper amount of auxiliary materials
Total 1000 tablets
The preparation method comprises the following steps: decocting the above four crude drugs with 12000ml of water for 2 times, wherein the decocting time is 1h each time, combining the decoctions, concentrating until the relative density is 1.12-1.20 (55-60 ℃), granulating the concentrated solution and a proper amount of conventional auxiliary materials, drying, uniformly mixing, pressing into 1000 tablets, and coating sugar coat or film coat to obtain the traditional Chinese medicine.
Example 2
Preparation of granules
Weighing the following formula, and preparing the granules according to the process of the granules
Rabdosia lophanthide 900g
American ginseng 200g
Osmanthus flower oil 10g
Proper amount of auxiliary materials
Total 1000g of granules
The preparation method comprises the following steps: decocting the rabdosia lophanthide with 5000ml of water for 2 times, each time for 1 hour, combining the decoctions, filtering, concentrating the filtrate to the relative density of 1.12-1.20 (55-60 ℃), and keeping the concentrated solution for later use; pulverizing radix Panacis Quinquefolii into fine powder, adding the above concentrated solution and appropriate amount of conventional adjuvants, mixing, granulating, drying, adding flos Osmanthi Fragrantis oil, mixing, and making into 1000g granule.
Example 3
Preparation of tea
Weighing according to the following formula, and preparing according to the process of the tea preparation
Rabdosia lophanthide 1000g
American ginseng 200g
Momordica grosvenori 50g
Proper amount of auxiliary materials
Total 1000g of granules
The preparation method comprises the following steps: decocting the above two materials with 4000ml water for 2 times, each time for 1 hr, mixing decoctions, filtering, concentrating the filtrate to appropriate concentration to obtain concentrated solution, pulverizing radix Panacis Quinquefolii into fine powder, adding the concentrated solution and appropriate amount of conventional adjuvants, mixing, pressing into blocks, and drying.
Example 4
Preparation of tea bag
Weighing according to the following formula, and preparing according to the process of tea bag
Rabdosia lophanthide 800g
American ginseng 40g
Osmanthus flower 40g
Total amount 880g
The preparation method comprises the following steps: mixing the above three crude drugs, and packaging into small bags to obtain teabag.
Example 5
Preparation of capsules
Weighing according to the following formula, and preparing according to capsule process
Rabdosia lophanthide 200g
American ginseng 200g
1000 hollow capsules
Total 1000 granules
The preparation method comprises the following steps: pulverizing the above two crude drugs into fine powder, sieving, mixing, and making into capsule.
Example 6
Preparation of oral liquid
Weighing according to the following formula, and preparing according to the process of oral liquid
Rabdosia lophanthide 600g
American ginseng 100g
Osmanthus flower oil 6g
Proper amount of auxiliary materials
A total volume of 1000ml
The preparation method comprises the following steps: adding 4000ml of water into the raw materials of the rabdosia lophanthide and the American ginseng, decocting twice, mixing decoctions, filtering, concentrating the filtrate under reduced pressure to obtain clear paste with the relative density of 1.10-1.30 (50-60 ℃), cooling, adding ethanol to ensure that the ethanol content reaches 50% -60%, standing, filtering, recovering the ethanol from the filtrate, concentrating the filtrate to obtain clear paste with the relative density of 1.10-1.30 (50-60 ℃), adding bay oil and a proper amount of water, uniformly mixing, adjusting the pH value, refrigerating, filtering, adding water to 1000ml, uniformly stirring, subpackaging and sterilizing to obtain the traditional Chinese medicine.
Example 7
Preparation of beverages
Weighing according to the following formula, and preparing according to the beverage process
Rabdosia lophanthide 4kg
American ginseng 2kg
Osmanthus fragrans 100g
Proper amount of auxiliary materials
Total amount of 100L
The preparation method comprises the following steps: soaking the above three raw materials in 60L water for 30min, heating and decocting for 1 hr, filtering, adding appropriate amount of conventional adjuvants, adding water to 100L, packaging, and sterilizing.
Example 8
Preparation of beverages
Weighing according to the following formula, and preparing according to the beverage process
Rabdosia lophanthide 4kg
American ginseng 2kg
Red date 1kg
Proper amount of auxiliary materials
Total amount of 100L
The preparation method comprises the following steps: soaking the above three raw materials in 70L water for 30min, heating and decocting for 1 hr, filtering, adding appropriate amount of conventional adjuvants, adding water to 100L, packaging, and sterilizing.
Example 9
Preparation of tea bag
Weighing according to the following formula, and preparing according to the process of tea bag
Rabdosia lophanthide 100g
American ginseng 500g
Total amount 600g
The preparation method comprises the following steps: mixing the above two crude drugs, and packaging into small bags to obtain teabag.
Example 10
Preparation of tea bag
Weighing according to the following formula, and preparing according to the process of tea bag
Rabdosia lophanthide 200g
American ginseng 200g
Longan 300g
Chinese wolfberry fruit 300g
A total of 1000g
The preparation method comprises the following steps: mixing the above four crude drugs, and packaging into small bags to obtain teabag.
Example 11
Preparation of tea bag
Weighing according to the following formula, and preparing according to the process of tea bag
Rabdosia lophanthide 800g
Ginseng 20g
Total 820g
The preparation method comprises the following steps: mixing the above two crude drugs, and packaging into small bags to obtain teabag.
Example 12
Preparation of tea bag
Weighing according to the following formula, and preparing according to the process of tea bag
Rabdosia lophanthide 800g
American ginseng 40g
Osmanthus flower 40g
Total amount 880g
The preparation method comprises the following steps: mixing the above three crude drugs, and packaging into small bags to obtain teabag.
Example 13
Preparation of oral liquid
Weighing according to the following formula, and preparing according to the process of oral liquid
Rabdosia lophanthide 600g
50g of pseudo-ginseng
Osmanthus flower oil 6g
Proper amount of auxiliary materials
A total volume of 1000ml
The preparation method comprises the following steps: decocting the raw materials of the rabdosia lophanthide and the pseudo-ginseng twice by adding 2000ml of water, mixing decoctions, filtering, concentrating the filtrate under reduced pressure to obtain clear paste with the relative density of 1.10-1.30 (50-60 ℃), standing, filtering, concentrating, adding the osmanthus flower oil, a proper amount of water and conventional auxiliary materials, uniformly mixing, adjusting the pH value, refrigerating, filtering, adding water to 1000ml, uniformly stirring, subpackaging and sterilizing to obtain the traditional Chinese medicine preparation.
The technical features of the embodiments described above may be arbitrarily combined, and for the sake of brevity, all possible combinations of the technical features in the embodiments described above are not described, but should be considered as being within the scope of the present specification as long as there is no contradiction between the combinations of the technical features.
The above-mentioned embodiments only express several embodiments of the present invention, and the description thereof is more specific and detailed, but not construed as limiting the scope of the invention. It should be noted that, for a person skilled in the art, several variations and modifications can be made without departing from the inventive concept, which falls within the scope of the present invention. Therefore, the protection scope of the present patent shall be subject to the appended claims.
Claims (10)
1. The linearstripe rabdosia herb composition for preventing or treating addiction material dependence is characterized in that active ingredients of the linearstripe rabdosia herb composition are prepared from the following raw materials: rabdosia lophanthide and Araliaceae Panax plant.
2. The linearstripe rabdosia herb composition as claimed in claim 1, wherein the active ingredient is prepared from the following raw materials in parts by weight: 1-100 parts of linearstripe rabdosia herb and 1-100 parts of a plant of the genus Panax of the family Araliaceae; preferably, the active ingredients are prepared from the following raw materials in parts by weight: 1-10 parts of rabdosia lophanthide and 1-10 parts of a plant of the genus Panax of the family Araliaceae; further preferably, the active ingredients are prepared from the following raw materials in parts by weight: 1-10 parts of rabdosia lophanthide and 1-2 parts of a plant of the genus Panax of the family Araliaceae.
3. The rabdosia lophanthide composition of claim 1 or 2, wherein the plant of genus Panax of family Araliaceae comprises at least one of Panax quinquefolium, Panax ginseng and Panax notoginseng.
4. A linearstripe rabdosia herb composition for improving mouthfeel and preventing or treating addiction substance dependence is characterized in that an active ingredient of the linearstripe rabdosia herb composition is prepared from the following raw materials: herba Rabdosiae Lophanthoidis, plant of Panax of Araliaceae, and at least one of flos Osmanthi Fragrantis, fructus Jujubae, fructus Lycii, arillus longan and fructus Siraitiae Grosvenorii.
5. The linearstripe rabdosia herb composition as claimed in claim 4, wherein the active ingredient is prepared from the following raw materials in parts by weight: 1-100 parts of linearstripe rabdosia herb, 1-100 parts of a plant of the genus Panax of the family Araliaceae and 1-100 parts of sweet osmanthus flower;
or the active ingredients are prepared from the following raw materials in parts by weight: 1-100 parts of linearstripe rabdosia herb, 1-100 parts of a plant of the genus Panax of the family Araliaceae, 1-100 parts of red dates and 1-100 parts of sweet osmanthus.
6. Use of the linearstripe rabdosia herb composition of any one of claims 1 to 5 for preparing a product for preventing or treating addiction to substance dependence.
7. The use of claim 6, wherein the addictive substance dependence is an alcohol or nicotine dependence.
8. Use of the composition of linearstripe rabdosia herb as claimed in any one of claims 1 to 5 for the preparation of a product for abstaining from alcohol or quitting smoking.
9. A product for preventing or treating addiction substance dependence, which comprises the linearstripe rabdosia herb composition as defined in any one of claims 1 to 5, and an auxiliary material.
10. The product of claim 9, wherein the product is a nutraceutical, food, or pharmaceutical product; further, the food is a teabag, a beverage, a granular food, a powdered food, a capsule-shaped food or a sheet-shaped food; the health care product is a liquid health care product, a granular health care product, a powdery health care product, a capsule health care product or a sheet health care product; the medicine is oral liquid, granules, powder, capsules or tablets.
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010917817.0A CN114129615B (en) | 2020-09-03 | 2020-09-03 | Rabdosia lophanthide composition and application thereof |
| AU2021101213A AU2021101213A4 (en) | 2020-09-03 | 2021-03-08 | Rabdosia Serra composition and its application |
| PCT/CN2021/092060 WO2022048176A1 (en) | 2020-09-03 | 2021-05-07 | Use of rabdosia serra, and rabdosia serra composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010917817.0A CN114129615B (en) | 2020-09-03 | 2020-09-03 | Rabdosia lophanthide composition and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114129615A true CN114129615A (en) | 2022-03-04 |
| CN114129615B CN114129615B (en) | 2023-01-31 |
Family
ID=75714398
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010917817.0A Active CN114129615B (en) | 2020-09-03 | 2020-09-03 | Rabdosia lophanthide composition and application thereof |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN114129615B (en) |
| AU (1) | AU2021101213A4 (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101612193A (en) * | 2009-07-17 | 2009-12-30 | 吉林紫鑫药业股份有限公司 | A kind of pharmaceutical composition that is used for the treatment of cholecystitis, cholangitis |
-
2020
- 2020-09-03 CN CN202010917817.0A patent/CN114129615B/en active Active
-
2021
- 2021-03-08 AU AU2021101213A patent/AU2021101213A4/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101612193A (en) * | 2009-07-17 | 2009-12-30 | 吉林紫鑫药业股份有限公司 | A kind of pharmaceutical composition that is used for the treatment of cholecystitis, cholangitis |
Non-Patent Citations (3)
| Title |
|---|
| 何钦等: "益胃化瘀散对胃癌前病变患者Ｔｈｌ／Ｔｈ２免疫漂移的影响", 《中草药》 * |
| 邓乔华等: "溪黄草资源现状及产业化发展的策略", 《2013年中国药学大会暨第十三届中国药师周论文集》 * |
| 钱玉飞: "人参香茶片的薄层层析鉴别", 《中国现代应用药学》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114129615B (en) | 2023-01-31 |
| AU2021101213A4 (en) | 2021-05-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103784611B (en) | It is a kind of that there is improvement sleep to help to alleviate composition and its application of pressure | |
| CN106605744A (en) | Composition capable of reducing fat, slimming, expelling toxin and beautifying, as well as preparation method thereof | |
| CN102293927B (en) | Compound Chinese medicinal preparation with antifatigue and antioxidation effects, and preparation method thereof | |
| CN101053621B (en) | Traditional Chinese medicinal composition for treating obesity and its preparation method | |
| CN105852084A (en) | Functional food composition capable of reducing weight and reducing blood lipid and preparation method of functional food composition | |
| CN112546167A (en) | Traditional Chinese medicine composition with spleen invigorating and dampness removing functions and preparation method and application thereof | |
| CN101199347A (en) | Pb excluding health care product and its preparation method | |
| KR101329187B1 (en) | Oriental medicine composition for chidren's anorexia and manufacturing method thereof | |
| CN115350256B (en) | Traditional Chinese medicine composition for treating insomnia and preparation method thereof | |
| CN110772564A (en) | Traditional Chinese medicine extract composition with depression mood regulating effect, preparation method thereof and traditional Chinese medicine preparation | |
| CN104337920B (en) | Traditional Chinese medicine composition for improving sleep quality | |
| CN114129615B (en) | Rabdosia lophanthide composition and application thereof | |
| CN109223886A (en) | Chinese medicine composition and its preparation method and application for invigorating the spleen to arrest diarrhea | |
| CN106177054A (en) | A kind of Hyperglycemic health care compositions comprising Cortex Mori and Pericarpium Citri Reticulatae | |
| CN114009773A (en) | Composition with sleep improving effect and preparation method and application thereof | |
| CN103977127B (en) | A kind of Chinese medicine composition for the treatment of infantile asthma and preparation method thereof | |
| CN112807415A (en) | Spleen and stomach warming and tonifying middle-jiao tea and preparation method thereof | |
| CN111248438A (en) | Medicated diet vegetarian product with health preserving effect and preparation method thereof | |
| CN114081171A (en) | Functional food composition with function of assisting in improving sleep | |
| CN114129614B (en) | Application of rabdosia lophanthide in preventing or treating nicotine dependence | |
| CN107595870A (en) | A kind of medicine composition capable of tonifying brain and soothing nerves, pharmaceutical preparation and application and preparation method | |
| JPH0798753B2 (en) | Composition for lowering blood glucose level | |
| WO2022048176A1 (en) | Use of rabdosia serra, and rabdosia serra composition | |
| CN107334927A (en) | A kind of preparation method for the medicine and its chewable tablets for treating children's indigestion and apositia | |
| CN101164595A (en) | Traditional Chinese medicine for curing anorexia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |